Biogen recently presented new data from its phase 1b PRIME study at the Ninth Clinical Trials on Alzheimer’s Disease (CTAD) meeting, which took place in San Diego, California.
The study involves aducanumab, which was developed to treat early Alzheimer’s disease (AD).
“The data at CTAD support the positive results we have seen in our phase 1b study of aducanumab, and they provide insight into the observed effects in patients treated for up to two years,” Biogen Vice President of Clinical Development Samantha Haeberlein said. “We are committed to advancing our global phase 3 program for aducanumab -- as well as the scientific understanding of Alzheimer’s disease -- so we can help identify a treatment for the many people affected by this terrible disease.”
The data included as part of the presentations featured the interim results from the titration cohort of the placebo-controlled period during the phase 1b trial and data from the long-term extension’s (LTE) first year.
Results of the trial support the phase 3 trials that involve aducanumab, which are currently ongoing. These trials are designed to assess aducanumab’s ability to treat early AD.
